Although sarcomas are a relatively uncommon group of malignancies, the last few years have brought advances in the understanding of the pathology, clinical behavior and the treatment of this heterogeneous group of tumors. Pazopanib is a Tyrosine Kinase Inhibitor that has been approved by the FDA in 2009 for use in soft tissue sacromas (STS). A few international studies have demonstrated the efficacy of Pazopanib administered following chemotherapy failure in STS, and no data exists concerning its efficacy in developing countries such as Lebanon. This study aims to conduct a retrospective analysis of patterns of Pazopanib treatment and its efficacy, as well as the STS subtypes most susceptible to Pazopanib treatment, at a single tertiary healthcare center in Lebanon, a developing country with available multidisciplinary treatment modalities.   

All patients 18 years and above STS patients diagnosed and treated with Pazopanib or chemotherapy as a second- or third-line treatment at the AUBMC between 2010-2015 are included. 

All patients 18 years and above STS patients diagnosed and treated with Pazopanib or chemotherapy as a second- or third-line treatment at the AUBMC between 2010-2015 are included. Baseline demographics, pathological data, and survival data of each patient will be collected from the medical records. Sample size expected is around 175 patients diagnosed between 2010 and 2015, with 20-30 cases diagnosed per year.